Skip to main content
SpringerLink
Log in

Upstream Therapy in the Treatment of Atrial Fibrillation

  • Chapter
  • First Online:
Book cover Atrial Fibrillation Therapy

Part of the book series: Current Cardiovascular Therapy ((CCT))

  • 1450 Accesses

Abstract

Nonelectrical factors which lead to inflammation and fibrosis and ultimately to structural remodelling have an important role in the generation of atrial fibrillation. Experimental studies and then observational and post hoc analyses of randomized controlled trials with different endpoints showed that the blockers of the renin-angiotensin-aldosteron system, the statins and the polyunsaturated fatty acids might prevent atrial remodelling and thus atrial fibrillation, being called upstream therapy. However, later large and valid studies did not confirm the efficacy of this upstream therapy.

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
Chapter
USD 29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 39.99
Price excludes VAT (USA)
  • Available as EPUB and PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD 54.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

References

  1. Burashnikov A, Antzelevitch C. Novel pharmacological targets for the rhythm control management of atrial fibrillation. Pharmacol Ther. 2011;132(3):300–13.

    Article  PubMed  CAS  Google Scholar 

  2. Van Gelder IC. Rhythm control for atrial fibrillation: non-channel antiarrhythmic drugs are en vogue. Cardiovasc Res. 2007;74:8–10.

    Article  PubMed  Google Scholar 

  3. Murray KT, Mace LC, Yang Z. Non-antiarrhythmic drug therapy for atrial fibrillation. Heart Rhythm. 2007;4:S88–90.

    Article  PubMed  Google Scholar 

  4. Ehrlich JR, Hohnloser SH, Nattel S. Role of angiotensin system and effects of its inhibition in atrial fibrillation: clinical and experimental evidence. Eur Heart J. 2006;27:512–8.

    Article  PubMed  CAS  Google Scholar 

  5. Dorian P, Singh BN. Upstream therapies to prevent AF. Eur Heart J Suppl. 2008;10:H11–31.

    Article  CAS  Google Scholar 

  6. Goette A, Lendeckel U. Electrophysiological effects of angiotensin II. Part I: signal transduction and basic electrophysiological mechanisms. Europace. 2008;10:238–41.

    Article  PubMed  Google Scholar 

  7. Cardin S, Li D, Thorin-Trescases N, Leung TK, Thorin E, Nattel S. Evolution of the atrial fibrillation substrate in experimental congestive heart failure: angiotensin-dependent and -independent pathways. Cardiovasc Res. 2003;60:315–25.

    Article  PubMed  CAS  Google Scholar 

  8. Milliez P, Girerd X, Plouin PF, Blacher J, Safar ME, Mourad JJ. Evidence for an increased rate of cardiovascular events in patients with primary aldosteronism. J Am Coll Cardiol. 2005;45:1243–8.

    Article  PubMed  CAS  Google Scholar 

  9. Reil JC, Hohl M, Selejan S, Lipp P, Drautz F, Kazakow A, et al. Aldosterone promotes atrial fibrillation. Eur Heart J. 2012;33:2098–108.

    Article  PubMed  CAS  Google Scholar 

  10. Burstein B, Nattel S. Atrial structural remodeling as an antiarrhythmic target. J Cardiovasc Pharmacol. 2008;52:4–10.

    Article  PubMed  CAS  Google Scholar 

  11. Liu T, Korantzopoulos P, Xu G, Shehata M, Li D, Wang Z, et al. Association between angiotensin-converting enzyme insertion/deletion gene polymorphism and atrial fibrillation: a meta-analysis. Europace. 2011;13:346–54.

    Article  PubMed  Google Scholar 

  12. Liu T, Li L, Korantzopoulos P, Goudevenos JA, Li G. Association between C-reactive protein and recurrence of atrial fibrillation after successful electrical cardioversion: a meta-analysis. J Am Coll Cardiol. 2007;49:1642–8.

    Article  PubMed  CAS  Google Scholar 

  13. Loffredo L, Angelico F, Perri L, Violi F. Upstream therapy with statin and recurrence of atrial fibrillation after electrical cardioversion. Review of the literature and meta-analysis. BMC Cardiovasc Disord. 2012;12:107.

    Article  PubMed  CAS  Google Scholar 

  14. Savelieva I, Kakouros N, Kourliouros A, Camm AJ. Upstream therapies for management of atrial fibrillation: review of clinical evidence and implications for European Society of Cardiology guidelines. Part I: primary prevention. Europace. 2011;13:308–28.

    Article  PubMed  Google Scholar 

  15. OCEBM Levels of Evidence Working Group. The Oxford 2011 levels of evidence. Oxford Centre for Evidence-Based Medicine. http://www.cebm.net/index.aspx?o=5653. Accessed 25 July 2013.

  16. Guyatt GH, Oxman AD, Vist GE, Kunz R, Falck-Ytter Y, Alonso-Coello P, Schünemann HJ, for the GRADE Working Group. GRADE: an emerging consensus on rating quality of evidence and strength of recommendations. BMJ. 2008;336:924–6.

    Google Scholar 

  17. Hill AB. The environment and disease: association or causation? Proc R Soc Med. 1965;58:295–300.

    PubMed  CAS  Google Scholar 

  18. Smit MD, Van Gelder IC. Upstream therapy of atrial fibrillation. Expert Rev Cardiovasc Ther. 2009;7:763–78.

    Article  PubMed  Google Scholar 

  19. Savelieva I, Kakouros N, Kourliouros A, Camm AJ. Upstream therapies for management of atrial fibrillation: review of clinical evidence and implications for European society of cardiology guidelines. Part II: secondary prevention. Europace. 2011;13:610–25.

    Article  PubMed  Google Scholar 

  20. Almroth H, Hoglund N, Boman K, Englund A, Jensen S, Kjellman B, et al. Atorvastatin and persistent atrial fibrillation following cardioversion: a randomized placebo-controlled multicentre study. Eur Heart J. 2009;30:827–33.

    Article  PubMed  CAS  Google Scholar 

  21. Schwartz GG, Chaitman BR, Goldberger JJ, Messig M. High-dose atorvastatin and risk of atrial fibrillation in patients with prior stroke or transient ischemic attack: analysis of the Stroke Prevention by Aggressive Reduction in Cholesterol Levels (SPARCL) trial. Am Heart J. 2011;161:993–9.

    Article  PubMed  CAS  Google Scholar 

  22. Camm AJ, Kirchhof P, Lip GY, Schotten U, Savelieva I, Ernst S, et al. Guidelines for the management of atrial fibrillation: the task force for the management of atrial fibrillation of the European Society of Cardiology (ESC). Eur Heart J. 2010;12:1360–420.

    Google Scholar 

  23. Kowey PR, Reiffel JA, Ellenbogen KA, Naccarelli GV, Pratt CM. Efficacy and safety of prescription omega-3 fatty acids for the prevention of recurrent symptomatic atrial fibrillation: a randomized controlled trial. JAMA. 2010;304:2363–72.

    Article  PubMed  CAS  Google Scholar 

  24. Bianconi L, Calo L, Mennuni M, Santini L, Morosetti P, Azzolini P, et al. n-3 Polyunsaturated fatty acids for the prevention of arrhythmia recurrence after electrical cardioversion of chronic persistent atrial fibrillation: a randomized, double-blind, multicentre study. Europace. 2011;13:174–81.

    Article  PubMed  Google Scholar 

  25. Disertori M, Latini R, Barlera S, Franzosi MG, Staszewsky L, Maggioni AP, et al. Valsartan for prevention of recurrent atrial fibrillation. N Engl J Med. 2009;360:1606–17.

    Article  PubMed  Google Scholar 

  26. Yusuf S, Healey JS, Pogue J, Chrolavicius S, Flather M, Hart RG, et al. Irbesartan in patients with atrial fibrillation. N Engl J Med. 2011;364:928–38.

    Article  PubMed  CAS  Google Scholar 

  27. Healey JS, Baranchuk A, Crystal E, Morillo CA, Garfinkle M, Yusuf S, et al. Prevention of atrial fibrillation with angiotensin-converting enzyme inhibitors and angiotensin receptor blockers: a meta-analysis. J Am Coll Cardiol. 2005;45:1832–9.

    Article  PubMed  CAS  Google Scholar 

  28. Maggioni AP, Fabbri G, Lucci D, Marchioli R, Franzosi MG, Latini R, et al. Effects of rosuvastatin on atrial fibrillation occurrence: ancillary results of the GISSI-HF trial. Eur Heart J. 2009;30:2327–36.

    Article  PubMed  CAS  Google Scholar 

  29. Ducharme A, Swedberg K, Pfeffer MA, Cohen-Solal A, Granger CB, Maggioni AP, et al. Prevention of atrial fibrillation in patients with symptomatic chronic heart failure by candesartan in the Candesartan in Heart failure: Assessment of Reduction in Mortality and morbidity (CHARM) program. Am Heart J. 2006;152:86–92.

    Article  PubMed  Google Scholar 

  30. Patti G, Chello M, Candura D, Pasceri V, D’Ambrosio A, Covino E, et al. Randomized trial of atorvastatin for reduction of postoperative atrial fibrillation in patients undergoing cardiac surgery: results of the ARMYDA-3 (Atorvastatin for Reduction of MYocardial Dysrhythmia After cardiac surgery) study. Circulation. 2006;114:1455–61.

    Article  PubMed  CAS  Google Scholar 

  31. GISSI-AF Investigators, Disertori M, Latini R, Barlera S, Franzosi MG, Staszewsky L, Maggioni AP, et al. Valsartan for prevention of recurrent atrial fibrillation. N Engl J Med. 2009;360:1606–17.

    Article  PubMed  Google Scholar 

  32. Yamashita T, Inoue H, Okumura K, Kodama I, Aizawa Y, Atarashi H, et al.; J-RHYTHM II Investigators. Randomized trial of angiotensin II-receptor blocker vs. dihydropiridine calcium channel blocker in the treatment of paroxysmal atrial fibrillation with hypertension (J-RHYTHM II study). Europace. 2011;13:473–9.

    Google Scholar 

  33. Goette A, Schön N, Kirchhof P, Breithardt G, Fetsch T, Häusler KG, et al. Angiotensin II-antagonist in paroxysmal atrial fibrillation (ANTIPAF) trial. Circ Arrhythm Electrophysiol. 2012;5:43–51.

    Article  PubMed  Google Scholar 

  34. Marik PE, Fromm R. The efficacy and dosage effect of corticosteroids for the prevention of atrial fibrillation after cardiac surgery: a systematic review. J Crit Care. 2009;24:458–63.

    Article  PubMed  CAS  Google Scholar 

  35. Christiansen CF, Christensen S, Mehnert F, Cummings SR, Chapurlat RD, Sørensen HT. Glucocorticoid use and risk of atrial fibrillation or flutter: a population-based, case–control study. Arch Intern Med. 2009;169:1677–83.

    Article  PubMed  Google Scholar 

  36. Madrid AH, Peng J, Zamora J, Marín I, Bernal E, Escobar C, et al. The role of angiotensin receptor blockers and/or angiotensin converting enzyme inhibitors in the prevention of atrial fibrillation in patients with cardiovascular diseases: meta-analysis of randomized controlled clinical trials. Pacing Clin Electrophysiol. 2004;27:1405–10.

    Article  PubMed  Google Scholar 

  37. Anand K, Mooss AN, Hee TT, Mohiuddin SM. Meta-analysis: inhibition of renin-angiotensin system prevents new-onset atrial fibrillation. Am Heart J. 2006;152:217–22.

    Article  PubMed  CAS  Google Scholar 

  38. Khatib R, Joseph P, Briel M, Yusuf S, Healey J. Blockade of the renin-angiotensin-aldosterone system (RAAS) for primary prevention of non-valvular atrial fibrillation: a systematic review and meta analysis of randomized controlled trials. Int J Cardiol. 2013;165:17–24.

    Article  PubMed  Google Scholar 

  39. Disertori M, Barlera S, Staszewsky L, Latini R, Quintarelli S, Franzosi MG. Systematic review and meta-analysis: renin-angiotensin system inhibitors in the prevention of atrial fibrillation recurrences: an unfulfilled hope. Cardiovasc Drugs Ther. 2012;26:47–54.

    Article  PubMed  CAS  Google Scholar 

  40. Bhuriya R, Singh M, Sethi A, Molnar J, Bahekar A, Singh PP, et al. Prevention of recurrent atrial fibrillation with angiotensin-converting enzyme inhibitors or angiotensin receptor blockers: a systematic review and meta-analysis of randomized trials. J Cardiovasc Pharmacol Ther. 2011;16:178–84.

    Article  PubMed  CAS  Google Scholar 

  41. Jibrini MB, Molnar J, Arora RR. Prevention of atrial fibrillation by way of abrogation of the renin-angiotensin system: a systematic review and meta-analysis. Am J Ther. 2008;15:36–43.

    Article  PubMed  Google Scholar 

  42. Schneider MP, Hua TA, Bohm M, Wachtell K, Kjeldsen SE, Schmieder RE. Prevention of atrial fibrillation by renin-angiotensin system inhibition a meta-analysis. J Am Coll Cardiol. 2010;55:2299–307.

    Article  PubMed  Google Scholar 

  43. Zhang Y, Zhang P, Mu Y, Gao M, Wang JR, Wang Y, et al. The role of renin-angiotensin system blockade therapy in the prevention of atrial fibrillation: a meta-analysis of randomized controlled trials. Clin Pharmacol Ther. 2010;88(4):521–31.

    Article  PubMed  CAS  Google Scholar 

  44. Huang G, Xu JB, Liu JX, He Y, Nie XL, Li Q, et al. Angiotensin-converting enzyme inhibitors and angiotensin receptor blockers decrease the incidence of atrial fibrillation: a meta-analysis. Eur J Clin Invest. 2011;41:719–33.

    Article  PubMed  Google Scholar 

  45. Johnston K, Stephens S. Effect of angiotensin-converting enzyme inhibitors and angiotensin receptor blockers on risk of atrial fibrillation before coronary artery bypass grafting. Ann Pharmacother. 2012;46:1239–44.

    Article  PubMed  Google Scholar 

  46. Liakopoulos OJ, Choi YH, Kuhn EW, Wittwer T, Borys M, Madershahian N, et al. Statins for prevention of atrial fibrillation after cardiac surgery: a systematic literature review. J Thorac Cardiovasc Surg. 2009;138:678–86.

    Article  PubMed  Google Scholar 

  47. Saso S, Vecht JA, Rao C, Protopapas A, Ashrafian H, Leff D, et al. Statin therapy may influence the incidence of postoperative atrial fibrillation: what is the evidence? Tex Heart Inst J. 2009;36:521–9.

    PubMed  Google Scholar 

  48. Yin L, Wang Z, Wang Y, Ji G, Xu Z. Effect of statins in preventing postoperative atrial fibrillation following cardiac surgery. Heart Lung Circ. 2010;19:579–83.

    Article  PubMed  CAS  Google Scholar 

  49. Rahimi K, Emberson J, McGale P, Majoni W, Merhi A, Asselbergs FW, et al.; PROSPER Executive. Effect of statins on atrial fibrillation: collaborative meta-analysis of published and unpublished evidence from randomised controlled trials. BMJ. 2011;342:d1250.

    Google Scholar 

  50. Chen WT, Krishnan GM, Sood N, Kluger J, Coleman CI. Effect of statins on atrial fibrillation after cardiac surgery: a duration- and dose–response meta-analysis. J Thorac Cardiovasc Surg. 2010;140(2):364–72.

    Article  PubMed  CAS  Google Scholar 

  51. Winchester DE, Wen X, Xie L, Bavry AA. Evidence of pre-procedural statin therapy a meta-analysis of randomized trials. J Am Coll Cardiol. 2010;56:1099–109.

    Article  PubMed  Google Scholar 

  52. Dong L, Zhang F, Shu X. Usefulness of statins pretreatment for the prevention of postoperative atrial fibrillation in patients undergoing cardiac surgery. Ann Med. 2011;43:69–74.

    Article  PubMed  CAS  Google Scholar 

  53. Fang WT, Li HJ, Zhang H, Jiang S. The role of statin therapy in the prevention of atrial fibrillation: a meta-analysis of randomized controlled trials. Br J Clin Pharmacol. 2012;74:744–56.

    Article  PubMed  CAS  Google Scholar 

  54. Fauchier L, Clementy N, Babuty D. Statin therapy and atrial fibrillation: systematic review and updated meta-analysis of published randomized controlled trials. Curr Opin Cardiol. 2013;28(1):7–18.

    Article  PubMed  Google Scholar 

  55. Santangeli P, Ferrante G, Pelargonio G, Dello Russo A, Casella M, Bartoletti S, et al. Usefulness of statins in preventing atrial fibrillation in patients with permanent pacemaker: a systematic review. Europace. 2010;12:649–54.

    Article  PubMed  Google Scholar 

  56. Liakopoulos OJ, Kuhn EW, Slottosch I, Wassmer G, Wahlers T. Preoperative statin therapy for patients undergoing cardiac surgery. Cochrane Database Syst Rev. 2012;4:CD008493.

    PubMed  Google Scholar 

  57. Khawaja O, Gaziano JM, Djoussé L. A meta-analysis of omega-3 fatty acids and incidence of atrial fibrillation. J Am Coll Nutr. 2012;31:4–13.

    Article  PubMed  CAS  Google Scholar 

  58. Cao H, Wang X, Huang H, Ying SZ, Gu YW, Wang T, et al. Omega-3 fatty acids in the prevention of atrial fibrillation recurrences after cardioversion: a meta-analysis of randomized controlled trials. Intern Med. 2012;51:2503–8.

    Article  PubMed  CAS  Google Scholar 

  59. He Z, Yang L, Tian J, Yang K, Wu J, Yao Y. Efficacy and safety of omega-3 fatty acids for the prevention of atrial fibrillation: a meta-analysis. Can J Cardiol. 2013;29:196–203.

    Article  PubMed  Google Scholar 

  60. Liu T, Korantzopoulos P, Shehata M, Li G, Wang X, Kaul S. Prevention of atrial fibrillation with omega-3 fatty acids: a meta-analysis of randomised clinical trials. Heart. 2011;97:1034–40.

    Article  PubMed  CAS  Google Scholar 

  61. Armaganijan L, Lopes RD, Healey JS, Piccini JP, Nair GM, Morillo CA. Do omega-3 fatty acids prevent atrial fibrillation after open heart surgery? A meta-analysis of randomized controlled trials. Clinics (Sao Paulo). 2011;66:1923–8.

    Google Scholar 

  62. Benedetto U, Angeloni E, Melina G, Danesi TH, Di Bartolomeo R, Lechiancole A, et al. n-3 Polyunsaturated fatty acids for the prevention of postoperative atrial fibrillation: a meta-analysis of randomized controlled trials. J Cardiovasc Med (Hagerstown). 2013;14:104–9.

    Article  CAS  Google Scholar 

  63. Fuster V, Rydén LE, Cannom DS, Crijns HJ, Curtis AB, Ellenbogen KA, et al.; American College of Cardiology/American Heart Association Task Force on Practice Guidelines; European Society of Cardiology Committee for Practice Guidelines; European Heart Rhythm Association; Heart Rhythm Society. ACC/AHA/ESC 2006 guidelines for the management of patients with atrial fibrillation: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines and the European Society of Cardiology Committee for Practice Guidelines (Writing Committee to Revise the 2001 guidelines for the management of patients with atrial fibrillation): developed in collaboration with the European Heart Rhythm Association and the Heart Rhythm Society. Circulation. 2006;114:e257–354.

    Google Scholar 

  64. American College of Cardiology Foundation, American Heart Association, European Society of Cardiology, Heart Rhythm Society, Wann LS, Curtis AB, Ellenbogen KA, Estes NA, Ezekowitz MD, Jackman WM, et al. Management of patients with atrial fibrillation (compilation of 2006 ACCF/AHA/ESC and 2011 ACCF/AHA/HRS recommendations): a report of the American College of Cardiology/American Heart Association Task Force on practice guidelines. Circulation. 2013;127:1916–26.

    Article  PubMed  Google Scholar 

  65. Camm AJ, Kirchhof P, Lip GY, Schotten U, Savelieva I, Ernst S, et al.; European Heart Rhythm Association, European Association for Cardio-Thoracic Surgery. Guidelines for the management of atrial fibrillation: the Task Force for the Management of Atrial Fibrillation of the European Society of Cardiology (ESC). Eur Heart J. 2010;31:2369–429.

    Google Scholar 

  66. Camm AJ, Lip GY, De Caterina R, Savelieva I, Atar D, Hohnloser SH, et al. 2012 focused update of the ESC Guidelines for the management of atrial fibrillation: an update of the 2010 ESC Guidelines for the management of atrial fibrillation. Developed with the special contribution of the European Heart Rhythm Association. Eur Heart J. 2012;33:2719–47.

    Article  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Carol Davila University of Medicine and Pharmacy Bucharest, Bucharest, Romania

    Cristian Baicus MD, PhD

  2. Department of Internal Medicine, Colentina University Hospital Bucharest, Soseaua Stefan cel Mare 19-21, sector 2, 020125, Bucharest, Romania

    Cristian Baicus MD, PhD

Authors
  1. Cristian Baicus MD, PhD
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Cristian Baicus MD, PhD .

Editor information

Editors and Affiliations

  1. Internal Medicine Clinic & Department of Cardiology, Colentina University Hospital, Bucharest, Romania

    Gheorghe-Andrei Dan

  2. Catalan Institute of Cardiovascular Sciences, Hospital Santa Creu i Sant Pau, Barcelona, Spain

    Antoni Bayés de Luna

  3. Cardiovascular Sciences Research, Centre Division of Clinical Sciences,, St. George's University of London, London, United Kingdom

    John Camm

Rights and permissions

Reprints and permissions

Copyright information

© 2014 Springer-Verlag London

About this chapter

Cite this chapter

Baicus, C. (2014). Upstream Therapy in the Treatment of Atrial Fibrillation. In: Dan, GA., Bayés de Luna, A., Camm, J. (eds) Atrial Fibrillation Therapy. Current Cardiovascular Therapy. Springer, London. https://doi.org/10.1007/978-1-4471-5475-4_4

Download citation

  • DOI: https://doi.org/10.1007/978-1-4471-5475-4_4

  • Published:

  • Publisher Name: Springer, London

  • Print ISBN: 978-1-4471-5474-7

  • Online ISBN: 978-1-4471-5475-4

  • eBook Packages: MedicineMedicine (R0)

Publish with us

Policies and ethics

Search

Navigation